Sign in
4

Changes in Ownership

Aquestive Therapeutics, Inc. Filed Acc 0001214659-26-014337

Chief Development Officer sold 7,197 shares at $3.55 ($25,526)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Davis Matthew W. · Chief Development Officer

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2026-11-12 Sale : show line 1 in the form 10b5-1 −7,197 $3.55 $25,526 87,500 D
Open-market sales · 7,197 sh · avg $3.55 · $25,526
Loading xslF345X06/marketforms-74306.xml…